Cytoreduction Results in High Perioperative Mortality and Decreased Survival in Patients Undergoing Pancreatectomy for Neuroendocrine Tumors of the Pancreas

Journal of Gastrointestinal Surgery

Volumn 10, Issue 10, 2006, Pages 1361-1370

  Bloomston, Mark ^a   Muscarella, Peter ^a   Shah, Manisha H ^a   Frankel, Wendy L ^a   Al Saif, Osama ^a   Martin, Edward W ^a   Ellison, E Christopher ^a  

^a Pathology (WLF)   (United States)

Author keywords

endocrine; islet cell carcinoma; Neuroendocrine; pancreas; survival

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL CARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PROPORTIONAL HAZARDS MODEL; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, ISLET CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33845406927     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2006.09.004     Document Type: Article

References (20)

1. Meko J.B., and Norton J.A. Endocrine tumors of the pancreas. Curr Opin Gen Surg (1994) 186-194
2. Bieligk S., and Jaffe B.M. Islet cell tumors of the pancreas. Surg Clin North Am 75 (1995) 1025-1040
3. Chu Q.D., Hill H.C., Douglass Jr. H.O., Driscoll D., Smith J.L., Nava H.R., and Gibbs J.F. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 9 (2002) 855-862
4. Evans D.B., Skibber J.M., Lee J.E., Cleary K.R., Ajani J.A., Gagel R.F., Sellin R.V., Fenoglio C.J., Merrell R.C., and Hickey R.C. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114 (1993) 1175-1181 discussion 1181-1182
5. Pederzoli P., Falconi M., Bonora A., Salvia R., Sartori N., Contro C., Marcucci S., and Bassi C. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital J Gastroenterol Hepatol 31 Suppl 2 (1999) S207-S112
6. Sato T., Konishi K., Kimura H., Maeda K., Yabushita K., Tsuji M., Demachi H., and Miwa A. Strategy for pancreatic endocrine tumors. Hepatogastroenterology 47 (2000) 537-539
7. Yeo C.J. Management of complications following pancreaticoduodenectomy. Surg Clin North Am 75 (1995) 913-924
8. Bassi C., Dervenis C., Butturini G., Fingerhut A., Yeo C., Izbicki J., Neoptolemos J., Sarr M., Traverso W., and Buchler M. Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery 138 (2005) 8-13
9. Nicholls A. Simple adenoma of the pancreas arising from an island of Langerhans. J Med Res 8 (1902) 385-395
10. Howland G., Campbell W., Maltby E., and Robinson W. Dysinsulinism: Convulsions and coma due to islet cell tumor of the pancreas, with operation and cure. JAMA 93 (1929) 674-679
11. Wilder R., Allan F., Power M., and Robertson H. Carcinoma of the islands of the pancreas: Hyperinsulinism and hypoglycemia. JAMA 89 (1927) 348-355
12. Zollinger R., and Ellison E. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142 (1955) 709-728
13. Norton J.A., Kivlen M., Li M., Schneider D., Chuter T., and Jensen R.T. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138 (2003) 859-866
14. Phan G.Q., Yeo C.J., Hruban R.H., Lillemoe K.D., Pitt H.A., and Cameron J.L. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (1998) 472-482
15. Jordan Jr. P.H. A personal experience with pancreatic and duodenal neuroendocrine tumors. J Am Coll Surg 189 (1999) 470-482
16. Matthews B.D., Heniford B.T., Reardon P.R., Brunicardi F.C., and Greene F.L. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 66 (2000) 1116-1122 discussion 1122-1123
17. Gupta S., Yao J.C., Ahrar K., Wallace M.J., Morello F.A., Madoff D.C., Murthy R., Hicks M.E., and Ajani J.A. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The M.D. Anderson experience. Cancer J 9 (2003) 261-267
18. Yao K.A., Talamonti M.S., Nemcek A., Angelos P., Chrisman H., Skarda J., Benson A.B., Rao S., and Joehl R.J. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130 (2001) 677-682 discussion 682-685
19. Osborne D.A., Zervos E.E., Strosberg J., Boe B.A., Malafa M., Rosemurgy A.S., Yeatman T.J., Carey L., Duhaine L., and Kvols L.K. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13 (2006) 572-581
20. Sarmiento J.M., Que F.G., Grant C.S., Thompson G.B., Farnell M.B., and Nagorney D.M. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: Outcomes of an aggressive approach. Surgery 132 (2002) 976-982 discussion 982-983